FDA Approves First and Only Treatment for AL Amyloidosis FDA Approves First and Only Treatment for AL Amyloidosis
Accelerated approval has been granted to daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone for treatment of newly diagnosed light chain amyloidosis.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 20, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to the deterior...
Source: Johnson and Johnson - January 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Covid Deaths Lowered in Trial of Tocilizumab and Sarilumab
The big dip in mortality shown in the trial of about 800 patients has caught some experts by surprise because previous studies of the drugs showed little benefit. (Source: NYT Health)
Source: NYT Health - January 8, 2021 Category: Consumer Health News Authors: Katherine J. Wu Tags: Clinical Trials Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) medRxiv Dexamethasone (Drug) Research Immune System Deaths (Fatalities) your-feed-healthcare Source Type: news
Dexamethasone Harmful in Chronic Subdural Hematoma Dexamethasone Harmful in Chronic Subdural Hematoma
The steroid, which is commonly used as a treatment for chronic subdural hematoma, appears to be doing more harm than good in this indication, a new randomized trial has shown.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 7, 2021 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news
Dexamethasone Not Favored for Chronic Subdural Hematoma
Dexamethasone worse than placebo with respect to favorable outcome at six months (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 30, 2020 Category: Cancer & Oncology Tags: Neurology, Oncology, Pharmacy, Surgery, Journal, Source Type: news
Dexamethasone Not Favored for Chronic Subdural Hematoma
WEDNESDAY, Dec. 30, 2020 -- Dexamethasone results in fewer favorable outcomes than placebo among patients with symptomatic chronic subdural hematoma, according to a study published online Dec. 16 in the New England Journal of Medicine.
Peter J.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 30, 2020 Category: Pharmaceuticals Source Type: news
The breakthrough medicines that could change the course of Covid
Dexamethasone demonstrates power of large-scale, randomised trials in finding effective medicinesCoronavirus – latest updatesSee all our coronavirus coverageIt remains one of the most dramatically successful outcomes in the battle against Covid-19. A cheap treatment for inflammation was found to save lives of seriously ill patients while a trio of much-touted therapies were shown to have no effect.It is now estimated that the discovery of the effectiveness of the drug dexamethasone has saved around 650,000 lives across the world, according to Professor Martin Landray, a founder of the Recovery programme – the world’s...
Source: Guardian Unlimited Science - December 27, 2020 Category: Science Authors: Robin McKie Observer Science Editor Tags: Coronavirus Medical research Biology UK news Infectious diseases Health World news Science Society Source Type: news
Dexamethasone May Nix Immunotherapy Benefit in Glioblastoma Dexamethasone May Nix Immunotherapy Benefit in Glioblastoma
Investigators found that baseline dexamethasone use was associated with poor overall survival (OS) in glioblastoma patients receiving anti –PD-1 or anti–PD-L1 therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 23, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
What Bill Gates Thinks About the State of the Fight Against COVID-19
Bill Gates isn’t about to be contemplating his touchdown dance yet. You don’t get to devote your life to battling the world’s most intractable problems by declaring victory before a fight is over. But in a letter Gates released this morning, headlined, “These breakthroughs will make 2021 better than 2020,” it’s clear that the co-director of the Bill and Melinda Gates Foundation is feeling pretty sanguine about the year ahead—particularly when it comes to COVID-19.
The Gates letter, which comes a month before the expected January release of Melinda Gates’s Annual Letter, sees ...
Source: TIME: Health - December 22, 2020 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized COVID-19 Source Type: news
Covid Guide: How to Get Through the Pandemic
Times are tough now, but the end is in sight. If we hunker down, keep our families safe during the holidays and monitor our health at home, life will get better in the spring. Here ’s how to get through it. (Source: NYT Health)
Source: NYT Health - December 19, 2020 Category: Consumer Health News Authors: Tara Parker-Pope Tags: Coronavirus Risks and Safety Concerns Disease Rates Chronic Condition (Health) Coronavirus (2019-nCoV) Dexamethasone (Drug) Telemedicine Vaccination and Immunization Travel Warnings Tests (Medical) Protective Clothing and Gear Winter ( Source Type: news
FDA approves selinexor for refractory or relapsed multiple myeloma
On December 18, 2020, the Food and Drug Administration approved selinexor (XPOVIO, Karyopharm Therapeutics Inc.) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 18, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Dexamethasone Therapy Poses High Risk for Patients With Chronic Subdural Hematoma Dexamethasone Therapy Poses High Risk for Patients With Chronic Subdural Hematoma
Treating chronic subdural hematoma with dexamethasone may do more harm than good, producing less favorable outcomes and more side effects than placebo, according to a new U.K. study that randomized 748 patients.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - December 17, 2020 Category: Surgery Tags: Internal Medicine News Source Type: news
Emergency Considerations in COVID-19 Vaccine Administration
Conclusion
The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities.
The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this management. ...
Source: JEMS Special Topics - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news
Emergency Considerations in COVID-19 Vaccine Administration
Conclusion
The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities.
The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this management. ...
Source: JEMS Operations - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news
Emergency Considerations in COVID-19 Vaccine Administration
Conclusion
The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities.
The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this management. ...
Source: JEMS: Journal of Emergency Medical Services News - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news
